Hutchison China MediTech Limited (LON:HCM)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 4,375 ($58.03) and last traded at GBX 4,375 ($58.03), with a volume of 59,532 shares changing hands. The stock had previously closed at GBX 4,017.50 ($53.29).

Several equities analysts have recently issued reports on HCM shares. Beaufort Securities reiterated a “buy” rating on shares of Hutchison China MediTech Limited in a research note on Tuesday, June 13th. Panmure Gordon reiterated a “buy” rating and issued a GBX 3,530 ($46.82) price target on shares of Hutchison China MediTech Limited in a research note on Thursday, June 22nd.

The firm’s market cap is GBX 2.69 billion. The stock’s 50-day moving average is GBX 3,797.85 and its 200 day moving average is GBX 5,992.65.

In other news, insider Karen Jean Ferrante purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average price of GBX 3,475 ($46.09) per share, with a total value of £347,500 ($460,936.46).

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.